An update from Mural Oncology Plc ( (MURA) ) is now available.
Mural Oncology is set to host an engaging Investor Day to discuss the progress of their pivotal clinical trials for nemvaleukin alfa, their cutting-edge cancer treatment candidate. Investors will gain insights into the trial designs and milestones, with key data readouts expected in early 2025 for treating platinum-resistant ovarian cancer and mucosal melanoma—areas with significant unmet medical needs. Additionally, the company will outline its interleukin-18 program, aiming to submit an Investigational New Drug application by the end of 2025. The event promises to delve into the potential of these novel therapies to transform the treatment landscape for cancer patients.
For a thorough assessment of MURA stock, go to TipRanks’ Stock Analysis page.
